Skip to main content

Genomic Data Solutions


Foundation Medicine provides genomic data solutions to accelerate and de-risk precision oncology development with our biopharma partners. Biopharma companies can extract key insights from our database to:

  • 识别或验证新靶点和途径

  • Discover and refine biomarkers to stratify patients

  • 通知试用设计和指示选择

  • Calculate prevalence to understand commercial potential and strategy


With over 400,000 patient profiles, FoundationCore is one of the largest databases of real-world comprehensive genomic profiling results in oncology. It’s also constantly evolving, typically adding more than 2,000 samples per week and has updated analyses and new biomarkers added to existing samples.

In addition to deep information on genomic alterations, computational biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) status are available, as are PD-L1 results.


Based on Data from FoundationCore



Ask our data anything: Analyze genomic data and extract powerful insights with one of the largest databases of real-world genomic profiles coupled with a powerful analytics platform. FoundationInsights can help provide answers to drive your goals.

Customized Genomic Analyses

Ask experts from the Cancer Genomic Research team for support with complex analyses. Deep collaborative interrogation of genomic data can include fields not currently reported clinically, such as loss of heterozygosity, somatic/germline zygosity, and novel and customized signatures.

Important Safety Information


FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based体外晚期癌症患者的实体肿瘤诊断试验,仅供在处方使用。该试验分析324个基因以及基因组特征,包括微卫星不稳定性(MSI)和肿瘤突变负担(TMB),并且是鉴定可能根据经批准的治疗产品标记的特定疗法受益的患者的伴侣诊断。可以报​​告额外的基因组发现,并且不规定的或决定性用于标记使用任何特定的治疗产品。使用测试不保证患者将与治疗匹配。否定结果不会排除发生变化的存在。有些患者可能需要活组织检查。对于完整的标签,包括伴侣诊断指示和重要风险信息,请访问。 

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based体外diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please